Along with the expansion of the global economy and the increased transnational movement of both people and goods, the threat of a pandemic of a serious infectious disease, involving new or recurring pathogens or multidrug-resistant bacteria, is looming and spreading globally at an alarming speed. To bring smiles back to those who suffer from infectious diseases, we at Shionogi continue to make efforts toward the discovery and development of therapeutic and prophylactic drugs for bacterial, fungal, and viral infections based on our excellent drug development and medical research capabilities. We also participate in the Global Health Innovative Technology Fund (GHIT), which is part of a public-private partnership commitment, conducting research on drugs for multidrug-resistant tuberculosis or neglected tropical diseases.
Trojan Horse: The discovery of a new antibiotic, Cefiderocol (S-649266)
We developed Cefiderocol (S-649266), a new siderophore cephalosporin having two distinct properties: (1) quick transmission through the strong outer membrane barrier via an active iron uptake pathway; and (2) high stability against carbabenemase which is capable of cleaving β-lactam antibiotics, including carbapenem derivatives.
FIC* Leading the World: Development of Baloxavir, a New Anti-Influenza Agent
Shionogi's Infectious Disease Study Group led by Mr. Takao Shishido worked on the development of new anti-influenza agents with a completely different mechanism of action from that of conventional drugs and found
S-033188 (Baloxavir Marboxil).
*FIC: First-in-Class (Especially novelty/effectiveness is high, original medicinal products which greatly change traditional treatment).